Melanie Sheen, MD

Community breast Med Onc in New Orleans @ochsnerhealth @ochsnercancer #MedTwitter #bcsm #WomenInMedicine Wife. Mom. Baker. French fry lover. Tweets are my own

[Sara Tolaney @stolaney1]

Excited to see Destiny Breast 03 now published in NEJM! T-DXd is the current 2L standard of care for metastatic HER2+ breast cancer, and more to come from this agent in the future!

@OncoAlert #bcsm

[Melanie Sheen, MD @msheenmd]

@Dr_RShatsky I used to go as a fellow, but it felt redundant after going to ASCO & SABCS. And I was living in Tampa, so the allure of warm Florida was my daily reality

[Matteo Lambertini, MD PhD @matteolambe]

Out in @Annals_Oncology long-term outcomes from BrighTNess supporting use of #carboplatin as part of standard neoadjuvant #chemotherapy in triple-negative #BreastCancer

@OncoAlert @Poggio_Fra @BenedettaConte5 @kevinpunie @delmastro_lucia @E_de_Azambuja

https://t.co/vdrMn3V7Xb

[Melanie Sheen, MD @msheenmd]

@Dr_RShatsky @drteplinsky Out here on Louisiana

[FDA Oncology @FDAOncology]

Read about FDA approvals from 2010-2020 for the treatment of breast malignancies and their relevant clinical trials, endpoints, and regulatory considerations - via @CCR_AACR. Important article by our breast cancer team in Division of Oncology 1!
https://t.co/yYIqYPI2Dt
#bcsm

[G💰 @WhenTheGsWalkIn]

Heavy on the "Who" in Who Dat tonight.

[Melanie Sheen, MD @msheenmd]

Beautiful patient story at #breastoration benefit tonight. Helping women navigate and afford reconstruction after breast cancer #bcsm cc: @OchsnerCancer

[Melanie Sheen, MD @msheenmd]

@DrSGraff If we’re going to keep going hybrid, we need more of this!

[Melanie Sheen, MD @msheenmd]

Impressive data from DestinyBreast-03 in subgroup of brain metastasis on #Enhertu. 28% complete response of brain mets!! #bcsm #SABCS21

[Melanie Sheen, MD @msheenmd]

Fascinating data from France using #Enhertu in cohorts of HER2 expression (high, moderate, and none) — 30% response rate in HER2 no expression! (caveat: small study) #bcsm #SABCS21

[Melanie Sheen, MD @msheenmd]

Excellent poster discussion on cancer survivors - cardiotoxicity, oncofertility, and supportive measures (return to work). “Survivorship starts at diagnosis” #bcsm #SABCS21

[Melanie Sheen, MD @msheenmd]

Nothing like being mid-conference and getting a call from your kid’s school that they had a close COVID contact and now has to quarantine for the remainder of the school year 😬😬😬 #workingparent #covidsucks

[Melanie Sheen, MD @msheenmd]

@Dr_RShatsky I said that yesterday!!

[Melanie Sheen, MD @msheenmd]

“Africa is not one country and being Black is not one thing” - @folopade bringing light to heterogeneity in genes and risk factors #WilliamMcGuireLecture #SABCS21 #bcsm #diversityinmedicine

[Melanie Sheen, MD @msheenmd]

Exploratory analyses of RxPONDER presented by @KalinskyKevin — return of menses -> worse IDFS. Asking the question again: is there a role for OFS to replace chemo on LN+ premenopausal pts #bcsm #SABCS21

[Melanie Sheen, MD @msheenmd]

Dramatic PFS improvement in Elacestrant vs Fulvestrant in early analysis with low side effect profile. Where will Elacestrant fit in the HR+ MBC paradigm? #SABCS21 #bcsm

[Melanie Sheen, MD @msheenmd]

Fascinating poster at AM session: rapid autopsy in MBC shows cancer cells in spleen, pancreas, & distant nodes — thank you to the patients who continued to advance our knowledge even after death #bcsm #SABCS21

[Melanie Sheen, MD @msheenmd]

Nadia Harbeck gives strategies and Q’s for de-escalation in TPBC #SABCS21 #bcsm

[Melanie Sheen, MD @msheenmd]

Powerhouse panel on equity in cancer research #SABCS21 #bcsm @tigerlilycares

[Melanie Sheen, MD @msheenmd]

Exciting news in the mTNBC population. Interested in the subset of pts who had prior sacituzumab #SABCS2021 #bcsm

[Jason A. Mouabbi MD @JAMouabbi]

Very promising new ADC Dato-DXd for metastatic TNBC with
ORR 34%
CBR 77%
30% had prior sacituzumab
#SABCS21 @OncoAlert #bcsm